MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$7,479K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of shor...
Stock-based compensation
Accrued compensation
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Purchase of short-term investmen...
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-10,510
-8,696
-8,613
-8,526
Depreciation and amortization
130
99
98
82
Stock-based compensation
2,271
1,629
790
704
Non-cash interest
36
36
43
55
Gain on termination of lease
52
-
-
-
Loss on remeasurement of warrant liabilities
0
0
-7
65
Non-cash lease expense
236
163
160
157
Provision for credit losses
739
402
52
24
Provision for excess and obsolete inventory
592
552
502
465
Accretion of discount on marketable securities
89
-
-
-
Other non-cash items
-21
-
0
-17
Accounts receivable, net
2,246
1,308
117
1,611
Inventory
803
771
1,008
736
Prepaid expenses and other assets
269
355
204
1,638
Accounts payable
670
-1,531
1,640
682
Accrued liabilities
922
-74
97
608
Accrued compensation
1,092
-2,976
1,351
1,296
Lease liabilities
-98
-177
-105
-103
Net cash used in operating activities
-7,358
-13,007
-5,321
-8,459
Purchase of short-term investments
12,000
-
24,000
-
Proceeds from maturities of short-term investments
12,000
-
-
-
Purchase of marketable securities
18,908
-
-
-
Purchase of property and equipment
121
79
73
159
Capitalized internal use software costs
628
127
157
184
Payment of initial direct costs related to operating leases
0
-
0
0
Net cash used in investing activities
-19,657
-206
-24,230
-343
Proceeds from initial public offering, net of underwriting discounts and commissions
-
-
0
93,465
Payments for deferred initial public offering costs
0
0
0
2,763
Proceeds from issuance of series c convertible preferred stock, net of issuance costs
0
0
0
0
Proceeds from term loan, net of issuance costs
-
-
0
-
Payment of issuance costs related to term loan modification
-
-
50
-
Proceeds from exercises of stock options
36
436
21
1
Proceeds from employee stock plan purchases
207
-
-
-
Net cash provided by financing activities
243
436
-29
90,703
(decrease) increase in cash, cash equivalents, and restricted cash
-26,772
-12,777
-29,580
81,901
Cash, cash equivalents, and restricted cash at beginning of the period
73,116
-
-
-
Cash, cash equivalents, and restricted cash at end of the period
46,344
-
-
-
Right-of-use asset obtained in exchange for lease liability
5,027
-
-
-
Property and equipment obtained in exchange for lease liability
270
-
-
-
Vesting of early exercised common stock options
21
-
-
-
Unpaid deferred offering and issuance costs
144
-
-
-
Capitalized internal use software included in accounts payable and accrued liabilities
59
-
-
-
Cash and cash equivalents, beginning of period
85,793
-
-
-
Restricted cash, beginning of period
100
-
-
-
Cash, cash equivalents, and restricted cash, beginning of period
73,116
85,893
115,473
40,225
Cash and cash equivalents, end of period
46,244
-
-
-
Restricted cash, end of period
100
-
-
-
Cash, cash equivalents, and restricted cash at end of the period
46,344
73,116
85,893
115,473
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from employee
stock plan purchases
$207K
Proceeds from exercises
of stock options
$36K
(-80.33%↓ Y/Y)
Net cash provided by
financing activities
$243K
(-97.43%↓ Y/Y)
(decrease) increase in
cash, cash...
-$26,772K
(-302.40%↓ Y/Y)
Canceled cashflow
$243K
Proceeds from maturities
of short-term...
$12,000K
Stock-based compensation
$2,271K
(424.48%↑ Y/Y)
Accrued compensation
$1,092K
(795.54%↑ Y/Y)
Accrued liabilities
$922K
(1282.05%↑ Y/Y)
Provision for credit
losses
$739K
(118.64%↑ Y/Y)
Accounts payable
$670K
(66900.00%↑ Y/Y)
Provision for excess and
obsolete inventory
$592K
(-32.11%↓ Y/Y)
Non-cash lease expense
$236K
(7.76%↑ Y/Y)
Depreciation and
amortization
$130K
(28.71%↑ Y/Y)
Non-cash interest
$36K
(-66.67%↓ Y/Y)
Other non-cash items
-$21K
Net cash used in
investing activities
-$19,657K
(-2060.11%↓ Y/Y)
Net cash used in
operating activities
-$7,358K
(51.58%↑ Y/Y)
Canceled cashflow
$12,000K
Canceled cashflow
$6,709K
Purchase of marketable
securities
$18,908K
Purchase of short-term
investments
$12,000K
Net loss
-$10,510K
(15.89%↑ Y/Y)
Capitalized internal use
software costs
$628K
(67.91%↑ Y/Y)
Purchase of property and
equipment
$121K
(-70.49%↓ Y/Y)
Accounts receivable, net
$2,246K
(-31.57%↓ Y/Y)
Inventory
$803K
(-15.03%↓ Y/Y)
Prepaid expenses and
other assets
$269K
(-46.20%↓ Y/Y)
Lease liabilities
-$98K
(-19.51%↓ Y/Y)
Accretion of discount on
marketable securities
$89K
Gain on termination
of lease
$52K
Buy us a coffee
CARLSMED, INC. (CARL)
CARLSMED, INC. (CARL)